Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

PURPOSE: Lurbinectedin suppresses the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus, and delays tumor growth in mice bearing Ewing sarcoma xenografts. On the basis of this rationale, lurbinectedin was evaluated in patients with relapsed Ewing sarcoma. PATIENTS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Braña, Irene, Longhi, Alessandra, Boni, Valentina, Delord, Jean-Pierre, Awada, Ahmad, Boudou-Rouquette, Pascaline, Sarantopoulos, John, Shapiro, Geoffrey I., Elias, Anthony, Ratan, Ravin, Fernandez, Cristian, Kahatt, Carmen, Cullell-Young, Martin, Siguero, Mariano, Zeaiter, Ali, Chawla, Sant P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306456/
https://www.ncbi.nlm.nih.gov/pubmed/35486638
http://dx.doi.org/10.1158/1078-0432.CCR-22-0696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306456/
https://www.ncbi.nlm.nih.gov/pubmed/35486638
http://dx.doi.org/10.1158/1078-0432.CCR-22-0696

Ejemplares similares